Ginkgo Bioworks Holdings (DNA) AI Stock Analysis

• Market Cap: $827.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.92
• Revenue Growth: 13.76%
• EPS Growth: 48.34%
• Country: US
• Employees: 834
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.68
• Shares Outstanding: 46,344,630
• 10 Day Avg. Volume: 1,617,626
• 30 Day Avg. Volume: 1,610,814
• PEG Ratio: -0.07
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.61
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 0.78
• Enterprise Value/Gross Profit: 3.86
• Enterprise Value/Ebitda: -0.31
• 1Y Price Target: $9.00
• Price Target Upside: -39.60% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 5

• Rating: 58 Neutral
• Price Target: $14.00 ▼(-6.04%Downside)

Ginkgo Bioworks Holdings faces substantial financial challenges with ongoing net losses and negative cash flows, significantly impacting its stock score. While there are positive technical indicators suggesting short-term momentum, the valuation remains unattractive. The earnings call provides some optimism with strategic cost reductions and revenue growth initiatives; however, macroeconomic challenges and a tough biotech capital market present risks.

Positive Factors

Contract Wins

The company announced a series of new contract and program wins during the quarter, highlighting the potential of its new services model within its CE business, with the most notable win being the $29 million ARPA-H contract award.

Revenue Growth

Ginkgo delivered 123 active revenue-generating cell programs, showing a 32% year-over-year growth, mainly driven by an increase in biopharma customers.

Negative Factors

Biotech Market Uncertainty

Biotech market uncertainty weighs on visibility and 2025 guidance.

Outsourcing Hesitancy

Ginkgo noted a considerable amount of 'hesitancy' in life sciences, particularly regarding outsourcing.

Ginkgo Bioworks Holdings Business Overview & Revenue Model

Company Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Ginkgo Bioworks primarily generates revenue through a combination of collaboration fees, milestone payments, and royalties from partnerships with companies across diverse industries. The company engages with partners to develop custom organisms that meet specific commercial needs, often entering into multi-year agreements that provide upfront payments and potential downstream revenue through royalties on sales of products developed using Ginkgo's engineered organisms. Additionally, Ginkgo Bioworks offers its expertise in cell programming as a service, providing access to its extensive biological engineering capabilities. Strategic collaborations and joint ventures further enhance its revenue streams, allowing the company to expand its reach and capitalize on its synthetic biology platform.

Ginkgo Bioworks Holdings Financial Statement Overview

Summary

Ginkgo Bioworks is facing financial challenges with significant net losses and negative operating cash flows. Despite maintaining reasonable leverage and gross profit margins, profitability and cash flow issues are prominent concerns.

Income Statement

Ginkgo Bioworks Holdings has shown a declining trend in revenue from 2022 to TTM (Trailing-Twelve-Months) 2025. The gross profit margin for TTM 2025 is approximately 73.55%, indicating efficient cost management relative to revenue. However, the company is facing significant losses with a net profit margin of -198.86% in TTM 2025, highlighting profitability challenges. EBIT and EBITDA margins are also negative, showing operational inefficiencies.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.67 in TTM 2025, indicating reasonable leverage. The equity ratio stands at 50.06%, suggesting a balanced equity position. However, the return on equity is negative due to the net losses, indicating challenges in generating returns for shareholders.

Cash Flow

Operating cash flow remains negative at -$281.8 million in TTM 2025, indicating cash outflows from core operations. The free cash flow to net income ratio is poor, reflecting challenges in converting earnings into cash. However, the company has shown some improvement in free cash flow since 2024, with a growth rate of 9.63%.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	227.04M	251.46M	477.71M	313.84M	76.66M
Gross Profit	188.49M	197.45M	273.49M	184.15M	61.05M
EBITDA	-484.39M	-821.29M	-2.06B	-1.81B	-108.58M
Net Income	-547.03M	-892.87M	-2.10B	-1.83B	-126.61M
Balance Sheet
Total Assets	1.38B	1.67B	2.54B	2.07B	675.15M
Cash, Cash Equivalents and Short-Term Investments	561.57M	944.07M	1.32B	1.55B	380.80M
Total Debt	467.73M	241.77M	442.59M	23.03M	17.00M
Total Liabilities	661.39M	568.19M	803.04M	503.61M	205.10M
Stockholders Equity	716.06M	1.10B	1.74B	1.51B	461.38M
Cash Flow
Free Cash Flow	-382.13M	-336.30M	-304.47M	-310.34M	-193.65M
Operating Cash Flow	-319.58M	-295.50M	-252.20M	-253.82M	-135.83M
Investing Cash Flow	-62.24M	-80.69M	-67.39M	-73.26M	-67.12M
Financing Cash Flow	-1.74M	-3.22M	95.34M	1.53B	90.32M

Ginkgo Bioworks Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNA, the sentiment is Positive. The current price of 14.9 is above the 20-day moving average (MA) of 11.20, above the 50-day MA of 9.29, and above the 200-day MA of 9.05, indicating a bullish trend. The MACD of 1.05 indicates Negative momentum. The RSI at 76.58 is Negative, neither overbought nor oversold. The STOCH value of 95.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNA.

Ginkgo Bioworks Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$772.58M	―		―	―	―
DNA	58 Neutral	$827.64M	―	-57.76%	―	13.76%	48.34%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
TRML	45 Neutral	$486.54M	―	-26.14%	―	―	74.59%
RAPP	44 Neutral	$565.71M	―	-33.14%	―	―	―
ERAS	34 Underperform	$484.42M	―	-45.82%	―	―	10.38%
SANA	33 Underperform	$1.16B	―	-71.44%	―	―	19.94%

Ginkgo Bioworks Holdings Corporate Events

Ginkgo Bioworks Holds Annual Shareholder Meeting, Elects Directors

On June 12, 2025, Ginkgo Bioworks Holdings, Inc. conducted its annual meeting of shareholders, where a significant majority of shares were represented. The meeting resulted in the election of seven directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, shareholders approved the executive compensation on an advisory basis, indicating broad support for the company’s leadership and strategic direction.

The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Ginkgo Bioworks Announces CFO Transition

On May 21, 2025, Ginkgo Bioworks announced the resignation of its Chief Financial Officer, Mark Dmytruk, effective May 30, 2025, as he transitions to another organization. Steven Coen, the current Chief Accounting Officer, will assume the role of CFO, bringing over 30 years of experience in public accounting and corporate finance. Coen’s appointment is expected to provide continuity and build upon the financial strategies laid out by Dmytruk, with a focus on achieving cost reduction targets and reaching Adjusted EBITDA breakeven by the end of 2026.

The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.